Biologics and biosimilars — Business MegaBrands 2026–27
Biologics are medicines produced in living cells, such as monoclonal antibodies, insulins and plasma-derived therapies; biosimilars are close equivalents of biologics whose patents have expired. Indian companies in this category develop, manufacture and market these products at home and overseas. Their presence brings down the cost of complex treatments for cancer, diabetes and autoimmune disease.
Slot BMB-177 · Biologics & Vaccines · 4 brands in contention · Business MegaBrand: to be announced in 2027
Brands in contention
Listed alphabetically. The order does not reflect evaluation.
| Company | MegaBrands 501 |
|---|---|
| Bharat Serums and Vaccines | |
| Biocon | Also a MegaBrand 501 |
| Enzene | |
| Reliance Life Sciences |
How this category is evaluated
Every brand in this category is assessed on WCRC's 50-parameter brand evaluation model, across five pillars: Brand Positioning & Recall, Trust & Sentiment, Product, Innovation & Delivery, Sustainability, Governance & ESG, and Digital & Financial Soundness. Scores are compared within the category, and the brand with the strongest result is named the Business MegaBrand. Read the methodology
Frequently asked
Which are the leading biologics and biosimilar companies in India?
In the Business MegaBrands 2026–27 cohort, the brands in contention for biologics and biosimilars are Bharat Serums and Vaccines, Biocon, Enzene, and Reliance Life Sciences. This is a list, not a ranking. WCRC will name one Business MegaBrand after its independent 50-parameter evaluation of every brand in contention.
Other categories in Biologics & Vaccines
All of Pharma, Life Sciences & Medtech · The 2026–27 cohort
Cite this page: WCRC, Business MegaBrands 2026–27, Biologics and biosimilars (Slot BMB-177), https://www.mostvaluablebrands.com/business-megabrands/2026-27/pharma-life-sciences-and-medtech/biologics-and-biosimilars/, accessed [date].
WCRC network: WCRC International · WCRC Leaders